Market revenue in 2024 | USD 28.7 million |
Market revenue in 2030 | USD 93.3 million |
Growth rate | 21.7% (CAGR from 2024 to 2030) |
Largest segment | Services |
Fastest growing segment | Services |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Services, NGS Commercial Software |
Key market players worldwide | Bio-Rad Laboratories Inc, DNAnexus, Qiagen NV, DNAstar, Pacific Biosciences of California Inc, Eurofins Scientific SE, Illumina Inc, PierianDx, Agilent Technologies Inc, Roche Holding AG, Alphabet Inc Class A, Thermo Fisher Scientific Inc, Golden Helix, Scigenom Labs, Genuity Science, Fabric Genomics (formerly Omicia), Congenica, Precigen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to next-generation sequencing data analysis market will help companies and investors design strategic landscapes.
Services was the largest segment with a revenue share of 54.36% in 2024. Horizon Databook has segmented the Japan next-generation sequencing data analysis market based on services, ngs commercial software covering the revenue growth of each sub-segment from 2018 to 2030.
There has been significant progress in understanding the molecular basis of cancer with the use of sequencing technologies in Japan. The Ministry of Health, Labor, and Welfare of Japan has approved multiple cancer gene panels based on NGS technology to be used in clinical practice.
For instance, the National Cancer Center, in collaboration with Sysmex Corporation, designed Onco Guide NCC Onco panel System that obtained approval in June 2019 for insurance coverage in Japan. This sequencing panel is used along with Agilent Sure Design.
Moreover, strategic initiatives undertaken by international companies to broaden the scope of NGS testing are expected to fuel growth of Japan NGS data analysis market. In June 2019, the National Cancer Center of Japan selected QIAGEN Clinical Insight (QCI) to support molecular profiling in the country’s cancer genomic medicine program.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan next-generation sequencing data analysis market , including forecasts for subscribers. This country databook contains high-level insights into Japan next-generation sequencing data analysis market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account